GlassScriptPhysician profile
Chelsea Driscoll
NPI 1457830465
$3,342.62
in general payments reported to CMS, 2019-2025
31 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $502 · 2024: $1,044 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795.24 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $431.41 | 2023-2025 | Caplyta |
| Lundbeck LLC | $293.95 | 2023-2025 | Rexulti |
| Alkermes, INC. | $286.49 | 2024-2025 | Aristada, Lybalvi |
| Pfizer INC. | $279.59 | 2023-2025 | |
| Axsome Therapeutics, INC. | $265.04 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $208.66 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Indivior INC. | $105.19 | 2024-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $75.39 | 2025 | Fanapt, Hetlioz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.47 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Almatica Pharma LLC | $62.74 | 2024 | Loreev Xr |
| Tris Pharma INC | $53.74 | 2024 | Dyanavel Xr |
| Gilead Sciences, INC. | $39.25 | 2023-2025 | |
| Glaxosmithkline, LLC. | $37.32 | 2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $34.12 | 2023 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $32.70 | 2025 | Azstarys |
| Novo Nordisk INC | $32.68 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.40 | 2023-2025 | Trintellix |
| Orexo US, INC. | $28.37 | 2023 | Zubsolv |
| Phathom Pharmaceuticals, INC. | $22.11 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $17.93 | 2024 | Uzedy |
| Ironshore Pharmaceuticals INC. | $16.92 | 2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $16.09 | 2024 | Ingrezza |
| Currax Pharmaceuticals LLC | $15.87 | 2023 | Contrave |
| Inspire Medical Systems, INC. | $15.33 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $14.63 | 2025 | Nuzyra |
| Amgen INC. | $14.06 | 2024 | Otezla, Repatha |
| Lilly USA, LLC | $13.73 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $13.61 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $13.50 | 2025 | Breztri |
| Organon LLC | $9.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Driscoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.